Pharmaceutical, Medical Devices, & Life Sciences

Our Approach

Pharmaceutical, medical device and life sciences products are in constant demand.

Litigation presents ongoing risk and quick resolution is critical. Using in-depth analysis, expert medical opinions, reviewing medical literature and applicable law, we develop cost-effective strategies to resolve our cases.

Not only do we help companies assess risk and get the best possible results, we set legal precedent and play an important role in establishing laws that benefit the industry.

We understand the difficulties of shepherding products through clinical trials, regulatory processes and ultimately bringing them to market.

Our unique blend of legal, scientific, technical and market experience includes a wide array of pharmaceutical and medical device products. We’ve resolved numerous spinal implant and latex glove cases without claim payments by our clients.

We’ve also successfully handled many other types of cases, including:

Diabetic drugs
NSAIDs
Blood products
Hip implants
Intraocular lenses
IUDs
Breast implants
Collagen implants

Quick resolutions to disputes are critical to a company’s success and the reputation of its product. We pursue early case disposition whenever possible. If trial is unavoidable, we aggressively defend cases in the courtroom at a national, regional and local level.

Who we work with

Pharmaceutical, medical device and life sciences companies

Media Clips

Takeda Subsidiary Seeks $130M for Drug Firm's Spinoff Fraud

Law360 | September 22, 2020

This article covers a trial to consider the amount of damages to be awarded to Millennium Pharmaceuticals for being fraudulently induced into investing more than $100 million into a spinoff of Harpoon Therapeutics. The story mentions Chicago Complex Commercial Disputes partners John Ruskusky and Lisa Sullivan for representing Millennium.

Aetna Blasts Conformis For Using Patient To Force Coverage

Law360 | July 24, 2020

Complex Commercial Disputes co-practice group leader and Boston partner Steve LaRose and Manchester associate Kierstan Schultz were mentioned in this article for representing Aetna in a suit regarding coverage for medical device manufacturer Conformis’ customized total knee implants.

Bayer Ducks Suit Over Birth Control Device Defect Claims

Law360 | June 25, 2020

This article, covering a federal judge’s dismissal of claims against NP client Bayer Corp. related to the company’s Essure birth control device, mentions Buffalo Complex Commercial Disputes partner Vivian Quinn and counsel Tracey Scarpello for representing Bayer.

A Year Out and a Supreme Court Case Still Leaves Patent Questions Unanswered

Intellectual Property & Technology Law Journal | December 05, 2019

Intellectual Property associates Sydney Pritchett, Ben Rosborough and Ravi Braich authored this patent alert about remaining questions and uncertainty following the U.S. Supreme Court ‘s ruling in Helsinn Healthcare S.A. v. Teva Pharmaceuticals U.S.

“Ascertainability” in pharmaceutical and medical device cases

Defense Research Institute | September 04, 2019

Complex Commercial Disputes partner Vivian Quinn and associate Tracey Scarpello, both of the Buffalo office, co-wrote this article in the Defense Research Institute’s publication, analyzing the impact of the ascertainability requirement on pharmaceutical and medical device class actions.

GSK wins access to records on researcher’s link to Zofran plaintiffs’ lawyers

Reuters Legal | July 25, 2019

This story mentions Boston Government Investigations and White Collar Defense partner Mark Seltzer for his representation of GlaxoSmithKline in an ongoing matter regarding the drugmaker’s antinausea medication, Zofran.

GSK gets 2nd chance to argue preemption in Zofran MDL

Law360 | July 10, 2019

The following articles mention Boston Government Investigations and White Collar Defense partners Mark Seltzer and Brian French for their representation of GlaxoSmithKline in an ongoing matter related to the pharmaceutical company’s anti-nausea drug Zofran. One of the issues is whether federal law pre-empts state law in the case.

Judge to seek FDA’s views on Zofran birth defect cases against GSK

Reuters Legal | July 10, 2019

GSK renews Zofran birth defect dismissal bid after Supreme Court ruling

Reuters Legal | June 04, 2019

This article mentions Boston Government Investigations and White Collar Defense partner Mark Seltzer for his representation of GlaxoSmithKline in an ongoing matter related to its anti-nausea medication Zofran.

Show More Show Less

Ideas